How Tissue Engineering and Sustainable Biomaterials Align With Global Development Goals

A comprehensive scientific review published in Biotechnology for Sustainable Materials examines how the expanding discipline of tissue engineering is aligning with the United Nations Sustainable Development Goals to merge medical innovation with environmental stewardship. Researchers Naresh Kasoju and Anagha Sunilkumar analyze how tissue engineering, which originally emerged in the late 1980s to construct biological substitutes that repair, maintain, or improve human tissue function, has transitioned from designing simple inert implants toward developing ecologically conscious, regenerative platforms. The authors detail how the foundational triad of tissue engineering—comprising patient-derived or stem cells, engineered biomaterial scaffolds, and biochemical signaling factors—increasingly incorporates green manufacturing processes, bio-based polymers, and closed-loop resource management. By charting the profound convergence between laboratory tissue regeneration and global sustainability frameworks, the review establishes that modern biomedical technologies can both restore complex physiological function and actively advance international sustainable development targets, notably Sustainable Development Goal 3, which centers on ensuring healthy lives and promoting well-being for all ages.

Tracing the historical trajectory of biomaterial science over the past fifty years, the review outlines how criteria for implantable materials have shifted across successive generations. First-generation biomaterials, such as bone cement, stainless steel, and Dacron, were intentionally selected to remain biologically inert, matching native tissue mechanical properties while minimizing adverse foreign-body responses from host immune systems. Second-generation materials, including titanium, bioactive glasses, poly(lactic-co-glycolic acid) (PLGA), and natural collagen, introduced bioactive capabilities that promoted osseointegration, direct tissue integration, and controlled biodegradation within healing environments. Currently, biomaterial development focuses on bioinductive matrices that replicate the native extracellular matrix (ECM) and dynamically stimulate cellular activities rather than merely serving as passive placeholders. Modern formulations encompass adaptable hydrogels, bio-based polymers derived from plants, animals, or microbial synthesis—such as bacterial cellulose—and renewable aliphatic polyesters. These biomass-derived alternatives minimize carbon footprints while presenting multifunctional characteristics necessary for wound care, artificial blood vessel manufacturing, and structural soft or bone tissue reconstruction across diverse patient demographics.

The mechanical, structural, and chemical properties of biomaterial scaffolds dictate cellular fate and subsequent tissue morphogenesis within the regenerative microenvironment. As the authors explain, scaffolds provide the physical framework that directs cell attachment, migration, proliferation, and differentiation throughout the porous void space. Surface chemistry plays a decisive role by modulating protein adsorption and cellular adherence, frequently enhanced through surface functionalization with bioactive peptides containing specific recognition sequences such as arginine-glycine-aspartic acid (RGD). Scaffold degradation kinetics must be precisely balanced to coincide with the rate of new extracellular matrix deposition, preventing premature mechanical collapse or lingering structural barriers that impede native reconstruction; this equilibrium can be regulated using enzyme-sensitive peptide crosslinkers. Concurrently, scaffold mechanical stiffness must match native tissue elasticity to guide mechanotransduction and lineage specification, pairing compliant substrates with neural or adipose tissue and stiffer mineralized matrices with bone or cartilage repair. Surface topography, including micro- and nanoscale patterning, further guides cellular alignment and stem cell differentiation even in the absence of exogenous biochemical cues.

Tissue engineering constructs are fabricated through two distinct methodological approaches: bottom-up assembly and top-down processing. Bottom-up strategies construct complex modular architectures by assembling microscopic units, such as individual cells, cell-laden hydrogels, and micro-tissues, using layer-by-layer deposition, organoid culture, and three-dimensional (3D) bioprinting. Three-dimensional bioprinting precisely positions bio-inks containing multiple cell types and biomimetic matrices to recreate heterogeneous anatomical geometries, though scaling up to large volumetric constructs remains challenging. Conversely, top-down approaches start with bulk materials or whole biological tissues that are sculpted into functional architectures using freeze-drying, molding, or electrospinning. Electrospinning produces interconnected nanofibrous meshes mimicking native fibrous extracellular architecture, whereas freeze-drying generates porous matrices that promote nutrient diffusion and cell infiltration. Top-down strategies also utilize organ decellularization, which strips donor organs of cellular antigens while retaining the native extracellular matrix architecture and mechanical integrity for subsequent recellularization with recipient cells. Both strategies present distinct technical trade-offs between microscopic architectural control and macroscopic mechanical robustness.

The therapeutic applications of tissue engineering span diverse anatomical systems, including skin, bone, cardiac, liver, and neural tissues. In dermatological repair, engineered living constructs such as Apligraf and Dermagraft have attained routine clinical adoption for treating severe burns and chronic non-healing ulcers, augmented by multilayered 3D bioprinting. Bone regeneration utilizes porous bioceramic scaffolds—such as hydroxyapatite, tricalcium phosphate, and bioactive glasses—seeded with mesenchymal stem cells and osteoinductive factors like bone morphogenetic protein-2. For cardiovascular conditions, patch grafts composed of fibrin or poly(glycerol sebacate) combined with external electrical stimulation assist in repairing infarcted myocardium, while bioresorbable stents fabricated from polylactic acid dissolve safely post-intervention. In hepatic and neural tissue engineering, bioprinted constructs integrating vascular channels support hepatocyte viability for drug screening, while conduit scaffolds fabricated from PLGA or chitosan combined with nerve growth factor guide axonal regeneration across peripheral nerve lesions. Additional specialized applications encompass corneal reconstruction, ear cartilage engineering, laryngeal tissue development, and dental pulp regeneration.

The review extensively evaluates how tissue engineering technologies intersect with specific targets established under Sustainable Development Goal 3. In the realm of maternal health and Target 3.1, engineered biomimetic models such as placenta-on-a-chip devices facilitate rigorous pharmacokinetic profiling during gestation, while injectable silk, alginate, collagen, and fibrin hydrogels offer minimally invasive solutions to reinforce cervical insufficiency or stem postpartum hemorrhage. Addressing Target 3.2, pediatric tissue engineering provides biomaterial scaffolds and biodegradable cardiovascular patches, valves, and vascular grafts that accommodate physiological growth, surmounting the infection, thrombosis, and static dimension limitations of traditional synthetic prosthetics in congenital heart defect management. Furthermore, advancing Target 3.7 for reproductive health, hydrogel-based systems incorporating alginate, collagen, and hyaluronic acid sustain in vitro follicle maturation for post-chemotherapy fertility preservation, microfluidic devices optimize assisted reproductive procedures, and specialized biomaterial meshes deliver pelvic floor tissue restoration. These interventions illustrate how targeted biomaterial fabrication addresses critical vulnerabilities across maternal, fetal, neonatal, and reproductive healthcare sectors.

The contributions to Sustainable Development Goal 3 extend further into Target 3.3 for infectious disease management, Target 3.4 for non-communicable diseases, and Targets 3.6 through 3.9. Against infectious pathogens, engineered mesoporous silica rods and injectable biomaterial matrices modulate local host immunity, recruit antigen-presenting cells, stabilize immunogenic proteins, and deliver targeted vaccines directly to regional lymph nodes. For non-communicable conditions, patient-derived stem cells seeded onto customized scaffolds yield personalized implants that minimize immunological rejection and restore organ function. Addressing Target 3.6, tissue-engineered epidermal grafts and osteogenic matrices improve recovery outcomes following traumatic road traffic injuries. In pursuit of Target 3.8, developing cost-effective, scalable biomaterial platforms expands universal healthcare access. Lastly, regarding Target 3.9, biomimetic lung-on-a-chip and liver tissue models serve as high-fidelity platforms for evaluating airborne and waterborne environmental pollutant toxicology, generating empirical data to strengthen regulatory safety standards and occupational guidelines.

Beyond direct healthcare delivery, tissue engineering actively reinforces several interconnected Sustainable Development Goals across education, industry, and environmental resource management. Under SDG 4 (Quality Education), bioprinted anatomically accurate tissue replicas serve as pedagogical instruments that enhance anatomical and pathological training. The sector drives SDG 8 (Decent Work and Economic Growth) by generating high-skilled biotechnology and pharmaceutical employment, while advancing SDG 9 (Industry, Innovation, and Infrastructure) through investments in microfluidics, electrospinning facilities, and multi-institutional academic-industrial consortia. The utilization of renewable biological feedstocks—such as silk fibroin obtained through sustainable sericulture and chitosan extracted from crustacean seafood processing waste—embodies SDG 12 (Responsible Consumption and Production) and protects marine and terrestrial ecosystems under SDGs 14 and 15. Furthermore, lowering material production costs mitigates international health inequities in low- and middle-income nations under SDG 10, while international bodies like the Tissue Engineering and Regenerative Medicine International Society cultivate global partnerships under SDG 17.

Despite significant laboratory milestones, integrating rigorous sustainability standards into tissue engineering poses pronounced technical, economic, and logistical challenges. Sourcing renewable biopolymers that simultaneously fulfill stringent clinical biocompatibility, batch uniformity, and mechanical performance requirements remains difficult, as conventional medical-grade synthetics rely heavily on non-renewable fossil resources. Additionally, green manufacturing processes and bio-derived raw materials frequently incur substantial initial expenditures, constraining commercial competitiveness against established non-degradable products. Advanced biofabrication modalities—particularly multi-axis 3D bioprinting, prolonged cleanroom culture, and medical sterilization protocols—are inherently energy-intensive, complicating institutional attempts to reduce operational carbon footprints without compromising tissue viability. Establishing effective waste disposal pathways for laboratory chemical reagents and biohazard residues presents further hurdles. Moreover, scaling production without sacrificing construct reproducibility is compounded by incomplete regulatory frameworks for sustainable medical technologies and the complex metrics required for comprehensive life cycle assessments across the entire implant lifespan.

Overcoming these multifaceted obstacles reveals promising pathways to embed circular economy principles and sustainable methodologies into future regenerative therapies. Continued innovations in upcycled biowaste utilization, bio-based polymers, and closed-loop material recycling offer environmentally benign scaffold alternatives without sacrificing cytocompatibility or regenerative efficacy. Integrating automated bioreactors, energy-efficient manufacturing pipelines, and renewable power sources can simultaneously lower production overheads and contract overall greenhouse gas emissions. Establishing standardized international benchmarks and dedicated life cycle assessment frameworks tailored for healthcare products will accelerate regulatory compliance and clinical translation. Furthermore, expanding interdisciplinary education across biological, engineering, environmental, and economic disciplines will cultivate a research workforce dedicated to eco-friendly biomedical innovation. Ultimately, by harmonizing regenerative clinical demands with sustainable resource stewardship, tissue engineering can deliver accessible, life-saving medical interventions while actively contributing to global environmental resilience and international social equity.

Subject of Research: Convergence of sustainable biomaterial engineering and United Nations Sustainable Development Goals

Article Title: Convergence of tissue engineering and sustainable development goals

Article References: Kasoju, N., & Sunilkumar, A. (2024). Convergence of tissue engineering and sustainable development goals. Biotechnology for Sustainable Materials, 1(1), Article 20. https://doi.org/10.1186/s44316-024-00021-y

Image Credits: AI Generated

DOI: 10.1186/s44316-024-00021-y

Keywords: Tissue Engineering, Biomaterials, Sustainable Development Goals, Regenerative Medicine, 3D Bioprinting, Biodegradable Scaffolds, Healthcare Sustainability, Biomedical Engineering, Convergence, tissue, engineering, sustainable